Inmed Pharmaceuticals Inc Revenue Growth Rates (INM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Inmed Pharmaceuticals Inc  (NASDAQ: INM)
 

INM's Revenue Growth by Quarter and Year

Inmed Pharmaceuticals Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/INM/growth
https://api.csimarket.com/api/v1/companies/INM/fundamentals
https://api.csimarket.com/api/v1/companies/INM/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
INM Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 0.00
FY 0.00

INMs Annual Revenue
Inmed Pharmaceuticals Inc's Revenue in the fiscal year 2026 $ 0.00 millions
Inmed Pharmaceuticals Inc's Revenue in the fiscal year 2025 $ 4.94 millions
Inmed Pharmaceuticals Inc's Revenue in the fiscal year 2024 $ 1.17 millions
Inmed Pharmaceuticals Inc's Revenue in the fiscal year 2023 $ 4.14 millions
Inmed Pharmaceuticals Inc's Revenue in the fiscal year 2022 $ 1.09 millions




INM Revenue first quarter 2024 Y/Y Growth Comment
Inmed Pharmaceuticals Inc in the first quarter 2024 recorded of $ 0.00 millions.

According to the results reported in the first quarter 2024, Inmed Pharmaceuticals Inc achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Inmed Pharmaceuticals Inc' s Revenue meltdown of -100% ranks overall at the positon no. in the first quarter 2024.


INM Revenue ( Y/Y Growth %) 2024
 FY 2023 FY 2022 FY 2021
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September -
FY   -

Financial Statements
Inmed Pharmaceuticals Inc's first quarter 2024 Revenue $ 0.00 millions INM's Income Statement
Inmed Pharmaceuticals Inc's first quarter 2023 Revenue $ 1.12 millions Quarterly INM's Income Statement


INM Revenue (Quarter on Quarter Growth %)

 2024
 FY 2023 FY 2022 FY 2021
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September -
FY (Year on Year)   -


Back to INM Growth rate Comparisons >> Back to INM Growth rate Comparisons >>


Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Dec 31 2023)   (Mar 31 2025)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
(Dec 31 2023)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Inmed Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


INM's I. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


INM's I. Quarter Q/Q Revenue Comment


Inmed Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking # 2936
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking # 1287


Cumulative Revenue growth Comment
Inmed Pharmaceuticals Inc realized trailing twelve months of $ 0 millions, in the Sep 30 2026, compare to Revenue of $ 5 millions a year ago.

In the Healthcare sector 447 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2936, from total ranking in previous quarter at 3398.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 448
Overall # 2936

Revenue TTM Y/Y Growth Statistics
High Average Low
239.77 %
 65.36 %
-17.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 275
S&P 500 # 1287
Cumulative Revenue growth Comment
Inmed Pharmaceuticals Inc realized trailing twelve months of $ 0 millions, in the Sep 30 2026, compare to Revenue of $ 5 millions a year ago.

In the Healthcare sector 447 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2936, from total ranking in previous quarter at 3398.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 448
Overall # 2936

Revenue TTM Y/Y Growth Statistics
High Average Low
239.77 %
65.36 %
-17.71 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Milestone Scientific Inc -5.95%$ -5.948 millions


About Inmed Pharmaceuticals Inc Revenue Growth Rates (INM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Inmed Pharmaceuticals Inc (CIK 1728328).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-115083
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Inmed Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.